Author:
Meltzer Eli O.,Hamilos Daniel L.,Hadley James A.,Lanza Donald C.,Marple Bradley F.,Nicklas Richard A.,Adinoff Allen D.,Bachert Claus,Borish Larry,Chinchilli Vernon M.,Danzig Melvyn R.,Ferguson Berrylin J.,Fokkens Wytske J.,Jenkins Stephen G.,Lund Valerie J.,Mafee Mahmood F.,Naclerio Robert M.,Pawankar Ruby,Ponikau Jens U.,Schubert Mark S.,Slavin Raymond G.,Stewart Michael G.,Togias Alkis,Wald Ellen R.,Winther Birgit
Subject
Immunology,Immunology and Allergy
Reference150 articles.
1. Rhinosinusitis: establishing definitions for clinical research and patient care;Meltzer;Otolaryngol Head Neck Surg,2004
2. EAACI position paper on rhinosinusitis and nasal polyps executive summary;Fokkens;Allergy,2005
3. US Food and Drug Administration. Title 21 Code of Federal Regulations. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm. Accessed June 1, 2006.
4. FDA: evidentiary standards for drug development and approval;Katz;NeuroRx,2004
5. Biomarkers and surrogate markers: an FDA perspective;Katz;NeuroRx,2004
Cited by
272 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献